Employees: 161
Size Cowealth Medical China (603122.SS) is a China Health Care company (Medical Specialties) with a market value of $562M, the 3414th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.61 on 18 Nov 2026.
Performance Over six months the shares fell 33.6%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue fell 17.6% over the last twelve months (peer median +14.4%); the operating margin is -5.3% (peer median 6.5%).
Valuation It trades at 5.9× enterprise value to sales against a peer median of 5.5× (9th most expensive of 19).
Capital Return on invested capital runs 6.0 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥640M | CN¥677M | CN¥937M | CN¥1.09B | CN¥1.28B |
| Revenue growth | — | -28% | -14% | -15% | — |
| Gross profit | CN¥121M | CN¥89.2M | CN¥172M | CN¥214M | CN¥245M |
| EBITDA | n/a | -CN¥16.7M | CN¥49.8M | CN¥73.6M | CN¥122M |
| Net income | -CN¥26.9M | -CN¥33.6M | CN¥27.6M | CN¥47.2M | CN¥82.7M |
| Free cash flow | -CN¥76.9M | CN¥6.19M | CN¥103M | -CN¥57.2M | -CN¥54.3M |
| Capital expenditure | CN¥11.7M | CN¥14.2M | CN¥31.8M | CN¥68.0M | CN¥25.9M |
| Total debt | CN¥188M | CN¥170M | CN¥122M | CN¥72.2M | CN¥140M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603122.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.9% | -0.8% | 2nd lowest of 19 |
| 6-month return | -33.6% | +1.1% | 4th lowest of 19 |
| Distance from 52-week high | -69.2% | -31.6% | 2nd lowest of 20 |
| Revenue growth (TTM) | -17.6% | +14.4% | 2nd lowest of 20 |
| Operating margin | -5.3% | 6.5% | 8th lowest of 20 |
| EV / Sales | 5.9× | 5.5× | 9th most expensive of 19 |
| ROIC minus cost of capital | -6.0 pp | -3.3 pp | 7th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 1.6× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | 6.7× | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | 18.3× | n/a | n/a |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 5.4× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 3.7× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 1.5× | 8.4% | +12.0% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | 14.3× | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | 6.7× | n/a | n/a |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | 6.4× | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 7.1× | -1.2% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 3.8× | 35.3% | +6.7% |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | 1.5× | 6.0% | -7.7% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 6.3× | 35.9% | +35.2% |